Curcumin, an active component of turmeric (Curcuma longa), and its effects on health

Critical Reviews in Food Science and Nutrition

Volumn 57, Issue 13, 2017, Pages 2889-2895

  Kocaadam, Betül ^a   Şanlier, Nevin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

curcumin; health; safety; Turmeric

Indexed keywords

ACCIDENT PREVENTION; BIOACTIVITY; FOOD PRODUCTS; HEALTH; PHYSIOLOGY;

ACTIVE COMPONENTS; ANTI-INFLAMMATORIES; ANTICANCER EFFECTS; CARDIO-VASCULAR DISEASE; CURCUMIN; PHYSIOLOGICAL ACTIVITY; PHYSIOLOGICAL EFFECTS; TURMERIC;

DISEASES;

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CURCUMIN; PLANT EXTRACT; TURMERIC EXTRACT;

CHEMISTRY; CHINA; CURCUMA; HUMAN; INDIA;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHINA; CURCUMA; CURCUMIN; HUMANS; INDIA; PLANT EXTRACTS;

EID: 85019081716     PISSN: 10408398     EISSN: 15497852     Source Type: Journal    
DOI: 10.1080/10408398.2015.1077195     Document Type: Article

References (74)

1. Aggarwal, B. B., and Harikumar, K. B., (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. Int J Biochem Cell Biol. 41:40–59.
2. Ahn, J., Lee, H., Kim, S., and Ha, T., (2010). Curcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/beta-catenin signaling. Am. J. Physiol. Cell. Physiol. 298:1510–1516.
3. Akpolat, M., Tarladaçalışır, Y., Uz, Y., Metin, M., and Kızılay, G., (2010). Kanser tedavisinde curcuminin yeri. Yeni Tıp Dergisi 27:142–147.
4. Ali, T., Shakir, F., and Morton, J., (2012). Curcumin and inflammatory bowel disease:Biological mechanisms and clinical implication. Digestion 85:249–255.
5. Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., and Aggarwal, B. B., (2008). Curcumin and cancer:An “old-age” disease with an “age-old” solution. Cancer Lett. 267:133–164.
6. Aziz, M. T., El-Asmar, M. F., El-Ibrashy, I. N., Rezq, A., Al-Malki, A., Wassef, M. A., Fouad, H. H., et al. (2012). Effect of novel water soluble curcumin derivative on experimental type-1 diabetes mellitus (short term study). Diabetology Metab. Synd. 4:30.
7. Aziz, M. T., El Ibrashy, I. N., Mikhailidis, D. P., Rezq, A. M., Wassef, M. A., Fouad, H. H., Ahmet, H. H., et al. (2013). Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. Diabetol Metab Syndr. 5:13.
8. Baliga, M. S., Joseph, N., Venkataranganna, M. V., Saxena, A., Ponemone, V., and Fayad, R., (2012). Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis:Preclinical and clinical observations. Food Funct 3:1109–1117.
9. Bright, J., (2007). Curcumin and autoimmune disease. Adv Exp Med Biol. 595:425–451.
10. Choudhary, S., Sinha, S., Zhao, Y., Banerjee, S., Sathyanarayana, P., Shahani, S., et al. (2011). NF-κB-inducing kinase (NIK) mediates skeletal muscle insulin resistance:Blockade by adiponectin. Endocrinol. 152:3622–3627.
11. Dantzer, R., O'Connor, J. C., Freund, G., Johnson, W., and Kelley, W., (2008). From inflammation to sickness and depression:When the immune system subjugates the brain. Nat. Rev. Neurosci. 9:46–56.
12. Devassy, J., Nwachukwu, I., and Jones, P., (2015). Curcumin and cancer:Barriers to obtaining a health claim. Nutr. Rev. 73(3):155–165.
13. Deogade, S., and Ghate, S., (2015). Curcumın:Therapeutıc applıcatıons in systemıc and oral health. Int. J. Biol. Pharm. Res. 6(4):281–290.
14. Dolai, S, Shi, W, Corbo, C, Sun, C, Averick, S, Obeysekera, D, et al. (2011). “Clicked” sugar-curcumin conjugate:Modulator of amyloid-beta and tau peptide aggregation at ultralow concentrations. ACS Chem Neurosci. 2:694–699.
15. Dong, H. P., Yang, R. C., Chunag, I. C., Huang, L. J., Li, H. T., Chen, H. L., and Chen, C. Y., (2012). Inhibitory effect of hexahydrocurcumin on human platelet aggregation. Nat. Prod. Commun. 7(7):883–884.
16. Duan, W., Yang, Y., Yan, J., Yu, S., Liu, J., Zhou, J., et al. (2012). The effects of curcumin post-treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway. Basic Res Cardiol. 107:263
17. European Food Safety Authority. (2014). Refined exposure assessment for curcumin (E 100). EFSA J. 12(10):3876
18. Ghorbani, Z., Hekmatdoost, A., and Mirmiran, P., (2014). Antihyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab. 12(4):e18081.
19. Guo, L. Y., Cai, X. F., Lee, J. J., Kang, S. S., Shin, E. M., Zhou, H. Y., et al. (2008). Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. Arch Pharm Res 31:490–496.
20. Gupta, S. C., Sung, B., Kim, J. H., Prasad, S., Li, S., and Aggarwal, B. B., (2013a). Multitargeting by turmeric, the golden spice:From kitchen to clinic. Mol Nutr Food Res. 57(9):1510–1528.
21. Gupta, S. C., Kismali, G., and Aggarwal, B. B., (2013b). Curcumin, a component of turmeric:From farm to pharmacy. Biofactors. 39(1):2–13.
22. Goel, A., Kunnumakkara, A. B., and Aggarwal, B. B., (2008). Curcumin as “curecumin”:From kitchen to clinic. Biochem Pharmacol. 75:787–809.
23. Hatcher, H., Planalp, R., Cho, J., Torti, F. M., and Torti, S. V., (2008). Curcumin:From ancient medicine to current clinical trials. Cell Mol Life Sci. 65:1631–1652.
24. Hayakawa, H., Kobayashi, T., Minamiya, Y., Ito, K., Miyazaki, A., Fukuda, T., and Yamamoto, Y., (2011). Development of a molecular marker to identify a candidate line of turmeric (Curcuma longa L.) with a high curcumin content. Am. J. Plant Sci. 2(1):5–26.
25. Holt, P., Katz, S., and Kirshoff, R., (2005). Curcumin therapy in inflammatory bowel disease:A pilot study. Digest. Dis. Sci. 50(11):2191–2193.
26. Hossain, A., and Ishimine, Y., (2005). Growth, yield, and quality of turmeric (Curcuma longa L.) cultivated on dark-red soil, gray soil, and red soil in Okinawa, Japan. Plant. Prod. Sci. 8(4):482–486.
27. İpek, E., Güray, Y., Demirkan, B., Güray, ⇐., Kafes, H., and Başyiğit, F., (2013). Kardiyoloji polikliniğine başvuran hastalarda bitkisel kökenli alternatif tedavilerin ve tamamlayıcı besin ⇐rünlerinin Tüketim prevalansı. Arch Turk Soc Cardiol. 41(3):218–224.
28. JECFA. (2004). Curcumin. (Prepared by Ivan Stankovic). Chemical and Technical Assessment Compendıum Addendum 11/Fnp 52 Add.11/29; Monographs 1 Vol.1/417.
29. Jurenka, J. S., (2009). Anti-inflammatory properties of curcumin, a majör constituent of Curcuma longa:A review of preclinical and clinical research. Altern Med Rev. 14(2):141–153.
30. Kannappan, R., Gupta, S. C., Kim, J. H., Reuter, S., and Aggarwal, B. B., (2011). Neuroprotection by spice-derived nutraceuticals:You are what you eat! Mol Neurobiol. 44:142–159.
31. Kuroda, M., Mimaki, Y., Nishiyama, T., Mae, T., Kishida, H., Tsukagawa, M., Takahashi, K., Kawada, T., Nakagawa, K., and Kitahara, M., (2005). Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull. 28(5):937–939.
32. Lai, C. S., Wu, J. C., Yu, S. F., Badmaev, V., Nagabhushanam, K., Ho, C. T., and Pan, M. H., (2011). Tetrahydrocurcumin is more effective than curcumin in preventing azoxymethane-induced colon carcinogenesis. Mol Nutr Food Res. 55:1819–1828.
33. Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., et al. (2006). Dose escalation of a curcuminoid formulation. BMC. Complem. Altern. Med. 6:10.
34. Li, F., Nitteranon, V., Tang, X., Liang, J., Zhang, G., Parkin, K. L., and Hu, Q., (2012). In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin. Food Chem. 135:332–337.
35. Lian, Y. T., Yang, X. F., Wang, Z. H., Yang, Y., Yang, Y., Shu, Y. W., Cheng, L. X., and Liu, K., (2013). Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities. Phytother Res. 27:1321–1327.
36. Liu, J. P., Feng, L., Zhu, M. M., Wang, R. S., Zhang, M. H., Hu, S. Y., et al. (2012). The in vitro protective effects of curcumin and demethoxycurcumin in Curcuma longa extract on advanced glycation end products-induced mesangial cell apoptosis and oxidative stress. Planta Med. 78:1757–1760.
37. Lubbad, A., Oriowo, A., and Khan, I., (2009). Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol. Cell. Biochem. 322:127–135.
38. Medzhitov, R., (2008). Origin and physiological roles of inflammation. Nature 454:428–435.
39. Mirzabeigia, P., Mohammadpour, A. H., Salarifar, M., Gholami, K., Mojtahedzadeh, M., and Javadi, M. R., (2015). The effect of curcumin on some of traditional and nontraditional cardiovascular risk factors:A pilot randomized, double-blind, placebo-controlled trial. Iran. J. Pharm. Res. 14(2):479–486.
40. Mishra, S., and Palanivelu, K., (2008). The effect of curcumin (turmeric) on Alzheimer's disease:An overview. Ann Indian Acad Neurol. 11(1):13–19.
41. Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H., Nagasawa, A., et al. (2008). The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118:868–878.
42. Monroy, A., Lithgow, G. J., and Alavez, S., (2013). Curcumin and neurodegenerative diseases. Biofactors. 39(1):122–132.
43. Murugan, P., and Pari, L., (2006). Antioxidant effect of tetrahydrocurcumin in streptozotocin–nicotinamide induced diabetic rats. Life Sciences. 79(18):1720–1728.
44. Mythri, R. B., and Srinivas Bharath, M. M., (2012). Curcumin:A potential neuroprotective agent in Parkinson's disease. Curr. Pharm. Des. 18:91–99.
45. Nabiuni, M., Nazari, Z., Abdolhamid Angaji, S., and Nejad, S., (2011). Neuroprotective effects of curcumin. Aust. J. Basic Appl. Sci. 5(9):2224–2240.
46. Pae, O., Jeong, S., Jeong, O., Kim, S., Kim, A., et al. (2007). Roles of heme oxygenase-1 in curcumin-induced growth inhibition in rat smooth muscle cells. Exp. Mol. Med. 39:267–277.
47. Patil, P., Jayaprakasha, G. K., Chidambara Murthy, K. N., and Vıkram, A., (2009). Bioactive compounds:Historical perspectives, opportunities, and challenges. J. Agric. Food Chem. 57:8142–8160.
48. Pubchem Open Chemistry Data Base, “Curcumin”. (2015). Access Date:22.07.2015 http://pubchem.ncbi.nlm.nih.gov/compound/curcumin#section=Top
49. Prasad, S., Gupta, S., Tyagi, A., and Aggarwal, B., (2014). Curcumin, a component of golden spice:From bedside to bench and back. Biotechnol. Adv. 32:1053–1064.
50. Qin, F., Huang, X., Zhang, H. M., and Ren, P., (2009). Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San to healthy volunteers and patients with functional dyspepsia:Influence of disease state. J. Pharm. Pharmacol. 61:125–129.
51. Rahman, I., and Biswas, S. K., (2009). In Regulation of Inflammation, Redox, and Glucocorticoid Signaling by Dietary Polyphenols, Surh, Y. J., Dong, Z., Cadenas, E., Packer, L., (Eds.), Boca Raton:CRC Press
52. Ravindran, J., Prasad, S., and Aggarwal, B. B., (2009). Curcumin and cancer cells:How many ways can curry kill tumor cells selectively? AAPS J. 11:495–510.
53. Sandur, S. K., Pandey, M. K., Sung, B., Ahn, K. S., Murakami, A., Sethi, G., et al. (2007). Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin, and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS independent mechanism. Carcinogen. 28:1765–1773.
54. Shehzad, A., Ha, T., Subhan, F., and Lee, S., (2011). New mechanism and anti-inflammatory role of curcumin in obesity and obesity related metabolic disease. Eur. J. Nutr. 50:151–161.
55. Shehzad, A., Khan, S., Shehzad, O., and Lee, Y. S., (2010). Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today 46(7):523–532.
56. Shehzad, A., and Lee, Y. S., (2010). Curcumin:Multiple molecular targets mediate multiple pharmacological actions–A review. Drugs Fut. 35:113–119.
57. Shehzad, A., Rehman, G., and Lee, Y., (2013). Curcumin in inflammatory diseases. Int. Union Biochem. Mol. Biology, Inc. 39(1):69–77.
58. Smith, G., Cappai, R., and Barnham, J., (2007). The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta. 1768:1976–1790.
59. Srimuangwong, K., Tocharus, C., Yoysungnoen Chintana, P., Suksamrarn, A., and Tocharus, J., (2012). Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 18:2383–2389.
60. Sohrab, G., Hosseinpour-Niazi, S., Hejazi, J., Yuzbashian, E., Mirmiran, P., and Azizi, F., (2013). Dietary polyphenols and metabolic syndrome among Iranian adults. Int J Food Sci Nutr. 64(6):661–667.
61. Somparn, P, Phisalaphong, C, Nakornchai, S., Unchern, S., and Morales, N. P., (2007). Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull. 30:74–78.
62. Sun, J., Zhao, Y., and Hu, J., (2013). Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One. 8:e67078.
63. Suskind, D. L., Wahbeh, G., Burpee, T., Cohen, M., Christie, D., and Weber, W., (2013). Tolerability of curcumin in pediatric inflammatory bowel disease:A forced-dose titration study. J Pediatr Gastroenterol Nutr. 56:277–279.
64. Taylor, R. A., and Leonard, M. C., (2011). Curcumin for inflammatory bowel disease:A review of human studies. Altern Med Rev. 16:152–156.
65. Tegenge, M. A., Rajbhandari, L., Shrestha, S., Mithal, A., Hosmane, S., and Venkatesan, A., (2014). Curcumin protects axons from degeneration in the setting of local neuroinflammation. Exp Neurol. 253C:102–110.
66. Tewtrakul, S., and Subhadhirasakul, S., (2007). Antiallergic activity of some selected plants in the Zingiberaceae family. J. Ethnopharmacol. 109:535–538.
67. Thangapazham, R. L., Sharma, A., and Maheshwari, R. K., (2007). Beneficial role of curcumin in skin diseases. Adv Exp Med Biol. 595:343–357.
68. Viswanath, P. K., and Christy, S. B., (2008). Immunomodulatory effects of curcumin in allergy. Mol. Nutr. Food Res. 52:1031–1039.
69. Wongcharoen, W., and Phrommintikul, A., (2009). The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 133:145–151.
70. Wu, J. C., Lai, C. S., Badmaev, V., Nagabhushanam, K., Ho, C. T., and Pan, M. H., (2011). Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells. Mol Nutr Food Res. 55:1646–1654.
71. Xie, L., Li, A X., and Takahara, S., (2011). Curcumin has bright prospects for the treatment of multiple sclerosis. Int. Immunopharmaco. 11:323–330.
72. Yano, S., Terai, M., Shimizu, K. L., Futagami, Y., Sekine, T., et al. (2000). Antiallergic activity of Curcuma longa (II). Features of inhibitory actions on histamine release from mast cells. Nat. Medicines. 54:325–329.
73. Zbarsky, V., Datla, K. P., Parkar, S., Rai, D. K., Aruoma, O. I., and Dexter, D. T., (2005). Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res. 39(10):1119–1125.
74. Zheng, A, Li, H., Wang, X., Feng, Z., Xu, J., and Cao, K., et al. (2014). Anticancer effect of a curcumin derivative B63:ROS production and mitochondrial dysfunction. Current Cancer Drug Targets 14:156–166.